<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK548412" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK548412/" /><meta name="ncbi_pagename" content="Clozapine - LiverTox - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Clozapine - LiverTox - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Clozapine" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2017/10/16" /><meta name="citation_pmid" content="31643731" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548412/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Clozapine" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2017/10/16" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548412/" /><meta name="description" content="Clozapine was the first atypical antipsychotic approved for treatment of schizophrenia. Because it is associated with severe and potentially fatal side effects (agranulocytosis), its use is restricted to refractory schizophrenia, and monitoring during therapy is required. Clozapine therapy is associated with serum aminotransferase elevations and in rare instances has been linked to clinically apparent acute liver injury." /><meta name="og:title" content="Clozapine" /><meta name="og:type" content="book" /><meta name="og:description" content="Clozapine was the first atypical antipsychotic approved for treatment of schizophrenia. Because it is associated with severe and potentially fatal side effects (agranulocytosis), its use is restricted to refractory schizophrenia, and monitoring during therapy is required. Clozapine therapy is associated with serum aminotransferase elevations and in rare instances has been linked to clinically apparent acute liver injury." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548412/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/Clozapine/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548412/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8A7B170467CDC100000000000E0005.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All Drug Records" href="/books/n/livertox/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" alt="Cover of LiverTox" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK548412_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK548412_dtls__"><div>Bethesda (MD): <a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>; 2012-.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/livertox/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Clotrimazole/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Cobimetinib/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK548412_"><span class="title" itemprop="name">Clozapine</span></h1><p class="small">Last Update: <span itemprop="dateModified">October 16, 2017</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="Clozapine.OVERVIEW"><h2 id="_Clozapine_OVERVIEW_">OVERVIEW</h2><div id="Clozapine.Introduction"><h3>Introduction</h3><p>Clozapine was the first atypical antipsychotic approved for treatment of schizophrenia. Because it is associated with severe and potentially fatal side effects (agranulocytosis), its use is restricted to refractory schizophrenia, and monitoring during therapy is required. Clozapine therapy is associated with serum aminotransferase elevations and in rare instances has been linked to clinically apparent acute liver injury.</p></div><div id="Clozapine.Background"><h3>Background</h3><p>Clozapine (kloe" za peen) is an atypical antipsychotic medication that appears to act both as a dopamine (D) and serotonin (5-HT2) receptor antagonist. Clozapine was introduced into clinical practice in 1971, but subsequently withdrawn in 1975 after reports of fatal agranulocytosis with its use. Nevertheless, because of its potent activity, clozapine was approved for restricted use in refractory schizophrenia in the United States in 1989 and only with surveillance using close monitoring of complete blood counts. As a result, use of clozapine has been limited. Clozapine is available as tablets of 25 and 100 mg in generic forms and under the brand names of Clozaril. The dosage of clozapine varies greatly, from 25 to as much as 900 mg daily based upon clinical response and tolerability. Common side effects include sedation, tremors, drooling, dizziness, headache, hypotension and syncope, dry mouth, constipation, and weight gain. Uncommon, but potential severe side effects include severe neutropenia, agranulocytosis, orthostatic hypotension and syncope, falls, seizures, cardiomyopathy, prolongation of the QTc interval, diabetes, dyslipidemia, weight gain and neuroleptic malignant syndrome.</p></div><div id="Clozapine.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>Serum enzyme elevations arise in up to two-thirds of patients on clozapine but are usually modest and resolve spontaneously after 6 to 12 weeks, often not requiring dose modification or discontinuation. Occasionally, serum enzyme elevations are associated with symptoms of nausea, weakness and abdominal discomfort, and therapy should be discontinued or managed with careful dose reduction.</p><p>Acute, clinically apparent episodes of liver injury with marked liver enzyme elevations and jaundice have been reported in more than a dozen patients receiving clozapine and is estimated to occur in ~1:2000 treated patients. The onset of injury is usually within a few days to several weeks after starting, and the typical pattern of serum enzyme elevations is hepatocellular or mixed, although cholestatic cases have also been described. Severe instances of acute liver injury with progressive hepatic failure and death or need for emergency transplantation have also been described. <a class="def" href="/books/n/livertox/glossary/def-item/glossary.eosinophilia/">Eosinophilia</a> or leukocytosis are not uncommon and fever and rash have been reported, although generally mild. Autoimmune markers are rare.</p><p>Likelihood score: B (very likely cause of clinically apparent liver injury).</p></div><div id="Clozapine.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>The mechanism by which clozapine causes liver injury is not known. Clozapine is extensively metabolized by the liver, partially via the cytochrome P450 system (CYP 1A2 and others), and production of a toxic intermediate of metabolism may underlie the frequent mild serum aminotransferase elevations that occur on clozapine therapy.</p></div><div id="Clozapine.Outcome_and_Management"><h3>Outcome and Management</h3><p>The serum aminotransferase elevations that occur on clozapine therapy are often self-limited and usually do not require dose modification or discontinuation of therapy. Most instances of clinically apparent liver injury due to clozapine have been mild-to-moderate in severity and rapidly resolve. Several cases of acute liver failure due to clozapine have been reported, but there have been no instances of chronic liver disease or vanishing bile duct syndrome. Persons with intolerance to clozapine can often tolerate other atypical antipsychotic agents, such as haloperidol, risperidone, quetiapine and olanzapine.</p><p>Drug Class: <a href="/books/n/livertox/AntipsychoticAgents/">Antipsychotic Agents</a>, Atypicals</p></div></div><div id="Clozapine.PRODUCT_INFORMATION"><h2 id="_Clozapine_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><div id="Clozapine.BPI" class="box"><p><b> REPRESENTATIVE TRADE NAMES</b></p><p>Clozapine &#x02013; Generic, Clozaril&#x000ae;</p><p><b>DRUG CLASS</b></p><p>Antipsychotic Agents</p><p><a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=Clozapine" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COMPLETE LABELING</a></p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div></div><div id="Clozapine.CHEMICAL_FORMULA_AND_STRUCTURE"><h2 id="_Clozapine_CHEMICAL_FORMULA_AND_STRUCTURE_">CHEMICAL FORMULA AND STRUCTURE</h2><div id="Clozapine.T1" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548412/table/Clozapine.T1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Clozapine.T1_lrgtbl__"><table><thead><tr><th id="hd_h_Clozapine.T1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">DRUG</th><th id="hd_h_Clozapine.T1_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">CAS REGISTRY NUMBER</th><th id="hd_h_Clozapine.T1_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_Clozapine.T1_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_Clozapine.T1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Clozapine</td><td headers="hd_h_Clozapine.T1_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/134987290" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">5786-21-0</a></td><td headers="hd_h_Clozapine.T1_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">C18-H19-Cl-N4</td><td headers="hd_h_Clozapine.T1_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><div class="graphic"><img src="/books/NBK548412/bin/Clozapine_Structure.jpg" alt="Clozapine Chemical Structure" /></div></td></tr></tbody></table></div></div></div><div id="Clozapine.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Clozapine_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 16 October 2017</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Clozapine.R1">Meyer JM. Pharmacotherapy of psychosis and mania. In, Brunton LL, Chabner BA, Knollman BC, eds. Goodman &#x00026; Gilman&#x02019;s the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011, pp. 417-56.<div><i>(Textbook of pharmacology and therapeutics).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R2">Larry D, Ripault MP. Hepatotoxicity of psychotropic drugs and drugs of abuse. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, pp. 443-62.<div><i>(Review of hepatotoxicity of psychiatric agents mentions that clozapine often causes mild to moderate ALT elevations but that &#x0201c;...clinically significant hepatotoxicity is uncommon&#x0201d;).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R3">Brodowski L, Matusewicz W, Urba&#x00144;ska-Ry&#x0015b; H, Krykowski E. [Acute bone marrow and liver damage during treatment with clozapine] [Article in Polish] Pol Tyg Lek 1984; 39: 721-2.  [<a href="/pubmed/6483677" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6483677</span></a>]<div><i>(25 year old man developed jaundice and bone marrow failure 5 weeks after starting clozapine [bilirubin 5.7 mg/dL, ALT 268 U/L], with ultimate recovery upon stopping).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R4">Schmidt G, Borsch G, Muller K-M, Ricken D. [Clozapine-induced cholestatic liver injury: a case report]. Dtsch med Wschr 1987; 112: 844-6.  [<a href="/pubmed/2884090" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2884090</span></a>]<div><i>(54 year old woman developed jaundice after 2 days of clozapine therapy [bilirubin 4.65 mg/dL, ALT 178 U/L, Alk P 239 U/L]; rapid recovery, and recurrence of ALT [82 U/L] and Alk P [328 U/L] elevations with rechallenge).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R5">Naber D, Leppig M, Grohmann R, Hippius H. Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia &#x02013; a retrospective study of 387 patients. Psychopharmacology 1989; 99: S73-6.  [<a href="/pubmed/2813668" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2813668</span></a>]<div><i>(Retrospective analysis of 387 inpatients with resistant schizophrenia receiving clozapine for an average of 49 days between 1978-88; liver enzymes were elevated in 8% of patients, but rarely required discontinuation [0.5%]).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R6">Dorta G, Siebenmann R, Frohli P, Freytag P, Koelz HR. Clozapin-induzierter cholestatistcher Ikterus: Ein Fallbericht. Z Gastroenterol 1989; 27: 388-90.  [<a href="/pubmed/2773535" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2773535</span></a>]<div><i>(65 year old woman developed fever followed by jaundice 10 days after starting clozapine [bilirubin 3.7 mg/dL, ALT 105 U/L, Alk P 902 U/L], but no rash or eosinophilia and resolution within 4 weeks of stopping).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R7">Gaertner JH, Fischer E, Hoss J. Side effects of clozapine. Psychopharmacology 1989; 99: S97-100.  [<a href="/pubmed/2813671" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2813671</span></a>]<div><i>(Retrospective analysis of 315 inpatients given clozapine; rise in serum enzymes in 61% of patients, &#x0003e;twice normal in 31%, absolute rise of 1 to 465 U/L; but no mention of jaundice or hepatitis).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R8">Baldessarini RJ, Frankenburg FR. Clozapine. A novel antipsychotic agent. N Engl J Med 1991; 14: 324: 746-54.  [<a href="/pubmed/1671793" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1671793</span></a>]<div><i> (Clozapine, the first atypical antipsychotic was introduced into use in US in 1990 with requirement for routine monitoring of blood counts; review of structure, mechanisms of action, metabolism, pharmacokinetics, efficacy and side effects; no mention of hepatotoxicity or ALT elevations).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R9">Kellner M, Wiedemann K, Krieg JC, Berg PA. Toxic hepatitis by clozapine treatment. Am J Psychiatry 1993; 150: 985-6.  [<a href="/pubmed/8494085" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8494085</span></a>]<div><i>(44 year old woman developed ALT elevations [675 U/L] during 5th week of clozapine therapy with normal Alk P and bilirubin, 28% eosinophils, resolving within 5 weeks of stopping, negative lymphocyte transformation tests).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R10">Eggert AE, Crismon ML, Dorson PG, Taylor RL. Clozapine rechallenge after marked liver enzyme elevation. J Clin Psychopharmacol 1994; 14: 425-6.  [<a href="/pubmed/7884025" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7884025</span></a>]<div><i>(40 year old man developed liver enzyme elevations 6 weeks after starting clozapine [bilirubin 0.6 mg/dL, ALT 594 U/L, Alk P167 U/L], without symptoms and resolving within 4 weeks of stopping; rechallenge led to minor, transient ALT elevations falling to normal on long-term use [&#x0003e;1 year]).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R11">Marinkovic D, Timotijevic I, Babinski T, Totic S, Paunovic VR. The side-effects of clozapine: a four year follow-up study. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18: 537-44.  [<a href="/pubmed/8078987" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8078987</span></a>]<div><i>(Among 100 hospitalized patients on clozapine for up to 4 years, 36% developed liver enzyme elevations usually within 4-6 weeks, all responding to a dose reduction).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R12">Hovens JE, Vogtl&#x000e4;nder LM, Verhoeve HA, Thunnissen PL. [Liver cell necrosis during administration of clozapine]. Ned Tijdschr Geneeskd 1994; 138: 363-5.  [<a href="/pubmed/8121527" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8121527</span></a>]<div><i>(38 year old woman developed malaise 1 week after starting clozapine [ALT rising to 444 U/L, Alk P 297 U/L, bilirubin 1.2 mg/dL], resolving within 1 month of stopping).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R13">Thatcher GW, Cates M, Bair B. Clozapine-induced toxic hepatitis. Am J Psychiatry 1995; 152: 296-7.  [<a href="/pubmed/7840371" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7840371</span></a>]<div><i>(35 year old man developed fatigue, abdominal pain, rash and fever 25 days after starting clozapine [bilirubin 2.2 mg/dL, ALT 719 U/L, GGT 70 U/L, eosinophils 7%], resolving within 5 weeks of stopping).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R14">Worrall R, Wilson A, Gullen M. Dystonia and drug-induced hepatitis in a patient treated with clozapine. Am J Psychiatry 1995; 152: 647-8.  [<a href="/pubmed/7694924" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7694924</span></a>]<div><i>(30 year old woman with chronic hepatitis C had rise in ALT from 67 to 424 U/L after 14 days of clozapine; ALT fell to normal [33 U/L] with lowering dose, but rose again [371 U/L] with subsequent dose escalation).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R15">Hummer M, Kurz M, Kurzthaler I, Oberbauer H, Miller C, Fleischhacker WW. Hepatotoxicity of clozapine. J Clin Psychopharmacol 1997; 17: 314-7.  [<a href="/pubmed/9241012" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9241012</span></a>]<div><i>(Weekly liver tests during haloperidol [n=71] or clozapine [n=167] therapy identified ALT elevations in 46% and 67% of patients which were &#x0003e;twice normal in 17% and 37%; Alk P elevations occurred in 14% vs 41%, but were never &#x0003e;twice normal; elevations usually appeared after 1-6 weeks of treatment and resolved even without dose modification).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R16">MacFarlane B, Davies S, Mannan K, Sarsam R, Pariente D, Dooley J. Fatal acute fulminant liver failure due to clozapine: a case report and review of clozapine-induced hepatotoxicity. Gastroenterology 1997; 112: 1707-9.  [<a href="/pubmed/9136851" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9136851</span></a>]<div><i>(39 year old man developed nausea, abdominal pain and jaundice after 8 weeks of clozapine therapy [bilirubin 14.7 mg/dL, ALT 1375 U/L, Alk P 290 U/L]; delay in stopping clozapine with subsequent worsening, ascites, coma and death).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R17">Markowitz JS, Grinberg R, Jackson C. Marked liver enzyme elevations with clozapine. J Clin Psychopharmacol 1997; 17: 70-1.  [<a href="/pubmed/9004073" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9004073</span></a>]<div><i>(27 year old man developed rising ALT after 4 weeks of clozapine therapy [bilirubin 1.2 mg/dL, ALT 1325 U/L, Alk P 144 U/L] without symptoms; values normalized within 3 weeks of stopping).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R18">Wirshing WC, Ames D, Bisheff S, Pierre JM, Mendoza A, Sun A. Hepatic encephalopathy associated with combined clozapine and divalproex sodium treatment. J Clin Psychopharmacol 1997; 17: 120-1.  [<a href="/pubmed/10950478" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10950478</span></a>]<div><i>(37 year old woman developed jaundice and sedation followed by ascites and encephalopathy 6 weeks after starting combination of valproate and clozapine [bilirubin 2.8 mg/dL, ALT 1525 U/L, high valproate levels], responding slowly to drug withdrawal; restarting clozapine was later tolerated without liver abnormalities).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R19">Young CR, Bowers MB Jr, Mazure CM. Management of the adverse effects of clozapine. Schizophr Bull 1998; 24: 381-90.  [<a href="/pubmed/9718630" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9718630</span></a>]<div><i>(Clozapine is highly effective in schizophrenia but has a high rate of adverse side effects, requiring discontinuation in 17%; liver enzyme elevations of &#x0003e;twice baseline values reported in 31% of patients, but usually mild and resolve even with continuing treatment).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R20">Thompson J, Chengappa KNR, Good CB, Baker RW, Kiewe RP, Bezner J, Schooler NR. Hepatitis, hyperglycemia, pleural effusion, eosinophilia, hematuria and proteinuria occurring early in clozapine treatment. Int Clin Psychopharmacol 1998; 13: 95-8.  [<a href="/pubmed/9669191" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9669191</span></a>]<div><i>(48 year old man developed jaundice 2 weeks after starting clozapine [bilirubin 8.7 mg/dL, ALT 100 U/L, Alk P 257 U/L], resolving within 4 weeks of switching to risperidone).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R21">Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686-96.  [<a href="/pubmed/10553730" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10553730</span></a>]<div><i>(Systematic review of 81 articles on weight change with antipsychotics, using change after 10 weeks to compare agents: clozapine +5.7, olanzapine +4.2, chlorpromazine +4.2, quetiapine +2.5, risperidone +1.7, loxapine +0.6, haloperidol +0.5, ziprasidone +0.3, molindone -0.1, and pimozide -2.7 kg).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R22">Jang SJ, Yi HT, Paek HJ, Lee SY. Clozapine-induced acute hepatitis. J Korean Neuropsychiatr Assoc 1999; 38: 227-33. Korean. Not in PubMed.<div><i>.</i></div></div></li><li><div class="bk_ref" id="Clozapine.R23">Panagiotis B. Grand mal seizures with liver toxicity in a case of clozapine treatment. J Neuropsychiatry Clin Neurosci 1999; 11: 117-8.  [<a href="/pubmed/9990571" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9990571</span></a>]<div><i>(30 year old man had a seizure after 4 weeks of clozapine therapy and found to have elevations in previously normal ALT [215 U/L] and Alk P [318 U/L] levels; drug stopped but time to resolution, bilirubin levels and symptoms not reported).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R24">Blum MW, Siegel AM, Meier R, Hess K. Neuroleptic malignant-like syndrome and acute hepatitis during tolcapone and clozapine medication. Eur Neurol 2001; 46: 158-60.  [<a href="/pubmed/11598337" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11598337</span></a>]<div><i>(70 year old woman given tolcapone and clozapine developed fever and stupor [ALT 71 rising to 988 U/L, CPK 531 rising to 3132 U/L, no mention of bilirubin], resolving within 10 days of stopping tolcapone, clozapine continued).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R25">Larsen JT, Clemensen SV, Klitgaard NA, Nielsen B, Br&#x000f8;sen K. [Clozapine-induced toxic hepatitis]. Ugeskr Laeger 2001; 163: 2013-4.  [<a href="/pubmed/11307364" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11307364</span></a>]<div><i>(49 year old woman developed fever, eosinophilia and hepatitis on 300 mg of clozapine and with high serum ALT levels; tolerated lower doses with serum monitoring; Abstract only).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R26">Gaertner I, Altendorf K, Batra A, Gaertner HJ. Relevance of liver enzyme elevations with four different neuroleptics: a retrospective review of 7,263 treatment courses. J Clin Psychopharmacol 2001; 21: 215-22.  [<a href="/pubmed/11270919" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11270919</span></a>]<div><i>(Retrospective review of 233 inpatients between 1980-92; an increase in ALT in 78% of patients on clozapine and 50% on haloperidol; 3-fold increase in ALT in 15% with clozapine and 2.4% with haloperidol; lower rates of 2-fold alkaline phosphatase elevations [1% and 0.8%]).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R27">Dumortier G, Cabaret W, Stamatiadis L, Saba G, Benadhira R, Rocamora JF, Aubriot-Delmas B, et al. [Hepatic tolerance of atypical antipsychotic drugs]. Encephale 2002; 28: 542-51.  [<a href="/pubmed/12506267" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12506267</span></a>]<div><i>(Review of reports of liver injury due to atypical antipsychotics).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R28">Mouradian-Stamatiadis L, Dumortier G, Januel D, Delmas BA, Cabaret W. Liver function tests during treatment with antipsychotic drugs: a case series of 23 patients. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 1409-11.  [<a href="/pubmed/12502031" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12502031</span></a>]<div><i>(Among 23 hospitalized patients on atypical antipsychotics, 6 had ALT or AST elevations by day 14 [ALT 48-158 U/L]; 2 were on risperidone, 2 olanzapine, 1 amisulpride, none clozapine; 1 on risperidone required stopping).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R29">Choice of an antipsychotic. Med Lett Drugs Ther 2003; 45: 102-4.  [<a href="/pubmed/14679353" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14679353</span></a>]<div><i>(&#x0201c;Clozapine is usually reserved for treatment of patients refractory to other drugs because it causes granulocytopenia&#x0201d; in ~1% of patients; marked sedation and weight gain are also common; no mention of hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R30">Kelly DL, Conley RR, Richardson CM, Tamminga CA, Carpenter WT Jr. Adverse effects and laboratory parameters of high-dose olanzapine vs. clozapine in treatment-resistant schizophrenia. Ann Clin Psychiatry 2003; 15: 181-6.  [<a href="/pubmed/14971863" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14971863</span></a>]<div><i>(Comparison of high doses of olanzapine vs clozapine in 8 week crossover study in 13 patients; ALT elevations in 66% of clozapine-, but in no olanzapine-treated patients; weight gain greater with olanzapine [~3.4 kg] than clozapine [~1.4 kg]).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R31">Prior TI, Baker GB. Interactions between the cytochrome P450 system and the second-generation antipsychotics. J Psychiatry Neurosci 2003; 28: 99-112.  [<a href="/pmc/articles/PMC161731/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC161731</span></a>] [<a href="/pubmed/12670127" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12670127</span></a>]<div><i>(Review of the interactions of the atypical antipsychotics with the P450 system; clozapine metabolized by CYP1A2 and 3A4 and possibly 2C9 and 2D6; risperidone by CYP2D6 and possibly 3A4; olanzapine by CYP1A2 and possibly 2D6; quetiapine and ziprasidone by CYP3A4).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R32">Bender S, Grohmann R, Engel RR, Degner D, Dittmann-Balcar A, Ruther E. Severe adverse drug reactions in psychiatric inpatients treated with neuroleptics. Pharmacopsychiatry 2004; 37 (Suppl 1): S46-53.  [<a href="/pubmed/15052514" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15052514</span></a>]<div><i>(Summary of severe adverse drug reactions reported among 35,293 inpatients; more common with atypicals [0.5-0.9%] than typical antipsychotic agents [0.02-0.2%], increased liver enzymes was most common adverse reaction to olanzapine, 4th in frequency to clozapine, 6th to haloperidol, 7th to risperidone; no mention of hepatitis or acute liver failure).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R33">Bell C, Delisle M. [Non-alcoholic liver steatorrhea secondary to clozapine]. Can J Psychiatry. 2004; 49: 575-6.  [<a href="/pubmed/15453113" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15453113</span></a>]<div><i>(46 year old woman gained 35 kg after 2 years of clozapine therapy and had ALT 100 U/L, but normal bilirubin with fatty liver on ultrasound; stopping therapy led to slow improvement in ALT; reintroduction at lower dose was tolerated without ALT elevations).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R34">Erdogan A, Kocabasoglu N, Yalug I, Ozbay G, Senturk H. Management of marked liver enzyme increase during clozapine treatment: a case report and review of the literature. Int J Psychiatry Med 2004; 34: 83-9.  [<a href="/pubmed/15242144" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15242144</span></a>]<div><i>(27 year old man developed rise in ALT [151 U/L] without bilirubin or Alk P elevations after 2 weeks of clozapine therapy, resolved in 10 days of stopping; rechallenge led to rise in ALT to 208 U/L, biopsy showed minimal changes and lowering dose followed by improvements in ALT, allowing long term therapy).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R35">Fong SY, Au Yeung KL, Tosh JM, Wing YK. Clozapine-induced toxic hepatitis with skin rash. J Psychopharmacol 2005; 19: 107.  [<a href="/pubmed/15671137" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15671137</span></a>]<div><i>(55 year old woman with onset of rash and fever 4 weeks after starting clozapine [bilirubin 1.3 mg/dL, ALT 595 U/L, Alk P 160 U/L, eosinophils rising from 3% to 31%], resolving within 1 month of stopping).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R36">Rettenbacher MA, Baumgartner S, Eder-Ischia U, Edlinger M, Graziadei I, Hofer A, Huber R, et al. Association between antipsychotic-induced elevation of liver enzymes and weight gain: a prospective study. J Clin Psychopharmacol 2006; 26: 500-3.  [<a href="/pubmed/16974192" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16974192</span></a>]<div><i>(Prospective study of 67 patients started on atypical antipsychotics [3 on clozapine]; ALT elevations were more frequent in 14 patients who gained &#x0003e;7% of body weight than in the 53 who did not [50% vs 19%] and mean changes in ALT, AST and GGT were greater; all were transient, asymptomatic and not associated with bilirubin elevations).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R37">Freund N. [Psychiatric patient with elevated liver values]. Praxis (Bern 1994) 2006; 95: 549-50.  [<a href="/pubmed/16625994" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16625994</span></a>]<div><i>(Case report of patient on clozapine who developed cholestatic liver injury 2 weeks after a course of amoxicillin/clavulanate).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R38">Luo D, McColl P, Walmsley R. Acute onset of ascites with clozapine-induced hepatitis. Intern Med J 2007; 37: 204-5.  [<a href="/pubmed/17316346" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17316346</span></a>]<div><i>(43 year old woman developed fever 2 weeks after starting clozapine, eventually with abdominal pain, [bilirubin 0.6 mg/dL, ALT 246 U/L, Alk P 132 U/L, eosinophilia], worsening on continuing clozapine with pleural effusion and ascites, resolving with stopping drug).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R39">Torrent C, Amann B, Sanchez-Moreno J, Colom F, Feinares M, Comes M, Rosa AR, et al. Weight gain in bipolar disorder: pharmacological treatment as a contributing factor. Acta Psychiatr Scand 2008; 118: 4-18.  [<a href="/pubmed/18498432" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18498432</span></a>]<div><i>(Review of frequency of weight gain in patients treated for bipolar disorders, most weight gain occurred with clozapine and olanzapine, but some weight gain also with quetiapine, risperidone, lithium, valproate and gabapentin; not with aripiprazole, ziprasidone, carbamazepine or lamotrigine).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R40">Flanagan RJ. Side effects of clozapine and some other psychoactive drugs. Curr Drug Saf 2008; 3: 115-22.  [<a href="/pubmed/18690989" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18690989</span></a>]<div><i>(Thorough review of multitude of side effects of clozapine; ALT elevations occur in 30-50% of patients, usually resolving after 6-12 weeks; jaundice reported in 84 of 136,000 [0.06%] and fulminant hepatitis in 0.001%; 2 cases).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R41">Gareri P, De Fazio P, Russo E, Marigliano N, De Fazio S, De Sarto G. The safety of clozapine in the elderly. Expert Opin Drug Saf 2008; 7: 525-38.  [<a href="/pubmed/18759705" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18759705</span></a>]<div><i>(Review on safety of clozapine; agranulocytosis occurred in 17 of 2260 patients [0.7%] in Finland; 50% fatality rate; ALT elevations in up to 10% of patients).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R42">Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J; Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135: 1924-34.  [<a href="/pmc/articles/PMC3654244/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3654244</span></a>] [<a href="/pubmed/18955056" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18955056</span></a>]<div><i>(Among 300 cases of drug induced liver disease in the US collected between 2004 and 2008, severe antidepressants [duloxetine, sertaline, fluoxetine, amitryptilline], but none of the atypical antipsychotic agents were implicated).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R43">Parsons B, Allison DB, Loebel A, Williams K, Giller E, Romano S, Siu C. Weight effects associated with antipsychotics: a comprehensive database analysis. Schizophr Res 2009; 110: 103-10.  [<a href="/pubmed/19321312" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19321312</span></a>]<div><i>(Analysis of weight gain in 21 placebo controlled trials [~3300 patients]; average monthly weight gain in pounds was +0.1 with placebo, +0.8 olanzapine, +0.6 risperidone, -0.3 ziprasidone. A 5% increase in weight occurred after one year in 13% of placebo, 39% haloperidol, 20% ziprasidone, 45% risperidone and 60% olanzapine treated subjects).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R44">Sacchetti E, Galluzzo A, Valsecchi P, Romeo F, Gorini B, Warrington L; on behalf of the INITIATE Study Group. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: The MOZART study. Schizophr Res 2009; 113: 112-21.  [<a href="/pubmed/19269791" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19269791</span></a>]<div><i>(Controlled trial of clozapine [300 mg/day] vs ziprasidone [80-160 mg/day] for 18 weeks; similar efficacy; weight gain +0.8 kg with clozapine vs -2.6 kg with ziprasidone; &#x0201c;no detrimental effects for either drug were observed with regard to ...liver functions&#x02026;&#x0201d;).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R45">Flanagan RJ. Fatal toxicity of drugs used in psychiatry. Hum Psychopharmacol 2008; 23 Suppl 1: 43-51.  [<a href="/pubmed/18098225" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18098225</span></a>]<div><i>(Deaths from fatal poisonings decreased in England and Wales between 1993-2004, antipsychotic overdose fatalities higher for phenothiazines than atypicals; deaths/million prescriptions being 29 for chlorpromazine, 15.5 thioridazine, 3.9 trifluoperazine, 13.3 olanzapine, 21 clozapine, and 31.3 quetiapine).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R46">Keane S, Lane A, Larkin T, Clarke M. Management of clozapine-related hepatotoxicity. J Clin Psychopharmacol 2009; 29: 606-7.  [<a href="/pubmed/19910731" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19910731</span></a>]<div><i>(Two cases; 52 year old woman developed fatigue and abdominal pain 8 days after starting clozapine [bilirubin normal, ALT 75 rising to 308 U/L, GGT 78 U/L], resolving within 4 weeks of stopping, but she was later able to tolerate long term therapy; 33 year old woman developed abnormal liver tests 5 weeks after starting clozapine [bilirubin normal, ALT 172 U/L, GGT normal], with improvement despite continuing therapy).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R47">Chang A, Krygier DS, Chatur N, Yoshida EM. Clozapine-induced fatal fulminant hepatic failure: a case report. Can J Gastroenterol 2009; 23: 376-8.  [<a href="/pmc/articles/PMC2706751/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2706751</span></a>] [<a href="/pubmed/19440569" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19440569</span></a>]<div><i>(~40 year old woman with schizophrenia developed nausea and jaundice 6 weeks after starting clozapine which was continued to 8 weeks [bilirubin 18.8 mg/dL, ALT 1668 U/L, Alk P 273 U/L], with progressive hepatic failure and death 4 weeks later).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R48">Chaplin AC, Curley MA, Wanless IR. Re: Recent case report of clozapine-induced acute hepatic failure. Can J Gastroenterol 2010; 24: 739-40; author reply 741.  [<a href="/pmc/articles/PMC3004447/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3004447</span></a>] [<a href="/pubmed/21165382" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21165382</span></a>]<div><i>(51 year old man developed jaundice 3 months after starting clozapine for schizophrenia [bilirubin 12.7 mg/dL, ALT 526 U/L, Alk P 1079 U/L] who died of cardiac arrest one week after presentation).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R49">G&#x000f3;mez Esp&#x000ed;n R, S&#x000e1;nchez Quiles I, Hallal H, Plaza J. [Acute hepatocellular lesion after successive exposure to clozapine and olanzapine in a patient with chronic hepatitis C infection]. Gastroenterol Hepatol 2010; 33: 150-2. Spanish.  [<a href="/pubmed/19914745" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19914745</span></a>]<div><i>(35 year old man with chronic hepatitis C developed asymptomatic rise in ALT [188 to 723 U/L] and GGT [134 to 648 U/L] 2 months after starting clozapine, improving on stopping and recurring one month after starting olanzapine [ALT 266 to 714 U/L], resolving upon stopping again).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R50">Ferrajolo C, Capuano A, Verhamme KM, Schuemie M, Rossi F, Stricker BH, Sturkenboom MC. Drug-induced hepatic injury in children: a case/non-case study of suspected adverse drug reactions in VigiBase. Br J Clin Pharmacol 2010; 70: 721-8.  [<a href="/pmc/articles/PMC2997312/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2997312</span></a>] [<a href="/pubmed/21039766" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21039766</span></a>]<div><i>(Worldwide pharmacovigilance database contained 9036 hepatic adverse drug reactions in children, olanzapine ranked 16th with 62 reports [adjusted reporting odds ratio of 3.1] and clozapine ranked 38th with 36 cases [0.8]).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R51">Reuben A, Koch DG, Lee WM; Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010; 52: 2065-76.  [<a href="/pmc/articles/PMC3992250/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3992250</span></a>] [<a href="/pubmed/20949552" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20949552</span></a>]<div><i>(Among 1198 patients with acute liver failure enrolled in a US prospective study between 1998 and 2007, 133 were attributed to drug induced liver injury, 4 of which were attributed to psychotropic agents [one each due to quetiapine, nefazodone, fluoxetine and venlafaxine], but none were attributed to clozapine or olanzepine).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R52">Kang SH, Lee JI. Eosinophilia, pleural effusion, hepatitis, and jaundice occurring early in clozapine treatment. Clin Psychopharmacol Neurosci 2013; 11: 103-5.  [<a href="/pmc/articles/PMC3766753/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3766753</span></a>] [<a href="/pubmed/24023555" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24023555</span></a>]<div><i>(47 year old woman with schizophrenia developed eosinophilia at 4 weeks, fever and myalgias at 5 weeks, and jaundice at 8 weeks after starting clozapine [bilirubin 6.0 mg/dL, ALT 254 U/L, GGT 573 U/L, eosinophils 12.9%], resolving rapidly on stopping and not recurring with olanzapine and haloperidol therapy).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R53">Brown CA, Telio S, Warnock CA, Wong AH. Clozapine toxicity and hepatitis. J Clin Psychopharmacol 2013; 33: 570-1.  [<a href="/pubmed/23764687" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23764687</span></a>]<div><i>(48 year old woman with schizophrenia developed fatigue 4 weeks after starting clozapine [ALT 444 U/L, bilirubin, Alk P and eosinophil counts normal], resolving rapidly on stopping and not recurring on haloperidol).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R54">Tucker P. Liver toxicity with clozapine. Aust N Z J Psychiatry 2013; 47: 975-6.  [<a href="/pubmed/23636912" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23636912</span></a>]<div><i>(21 year old man with schizophrenia developed fatigue after 3 weeks of clozapine [bilirubin 1.5 rising to 6.5 mg/dL, ALT 794 to 2282 U/L, GGT normal to 164 U/L, with leukocytosis], resolving within 4 weeks of stopping and not recurring on sulpride).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R55">Nielsen J, Correll CU, Manu P, Kane JM. Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided? J Clin Psychiatry 2013; 74: 603-13.  [<a href="/pubmed/23842012" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23842012</span></a>]<div><i>(Systematic review of 81 studies of clozapine suggests that discontinuation of clozapine is warranted for ALT or AST elevations beyond 3 times ULN, but that dose lowering and rechallenge is sometimes possible).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R56">Bj&#x000f6;rnsson ES, Bergmann OM, Bj&#x000f6;rnsson HK, Kvaran RB, Olafsson S. Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013; 144: 1419-25.  [<a href="/pubmed/23419359" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23419359</span></a>]<div><i>(In a population based study of drug induced liver injury from Iceland, 96 cases were identified over a 2 year period, but none were attributed to clozapine or olanzapine).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R57">Kane JP, O'Neill FA. Clozapine-induced liver injury and pleural effusion. Ment Illn 2014; 6: 5403.  [<a href="/pmc/articles/PMC4274456/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4274456</span></a>] [<a href="/pubmed/25553232" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25553232</span></a>]<div><i>(48 year 47 year old woman with schizophrenia developed fatigue and fever [bilirubin 1.4 mg/dL, ALT 894 U/L, Alk P 220 U/L, eosinophils 2390], with worsening of abnormalities until clozapine was stopped, whereupon all tests returned to normal within 6 weeks).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R58">Douros A, Bronder E, Andersohn F, Klimpel A, Thomae M, Sarganas G, Kreutz R, et al. Drug-induced liver injury: results from the hospital-based Berlin Case-Control Surveillance Study. Br J Clin Pharmacol 2015; 79: 988-99.  [<a href="/pmc/articles/PMC4456131/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4456131</span></a>] [<a href="/pubmed/25444550" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25444550</span></a>]<div><i> (Among 76 cases of suspected drug induced liver injury and 377 controls enrolled in a German, prospective hospital based registry, 5 cases but only 1 control were receiving clozapine [odds ratio=34.6]).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R59">Wu Chou AI, Lu ML, Shen WW. Hepatotoxicity induced by clozapine: a case report and review of literature. Neuropsychiatr Dis Treat 2014; 10: 1585-7.  [<a href="/pmc/articles/PMC4155895/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4155895</span></a>] [<a href="/pubmed/25210451" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25210451</span></a>]<div><i> (45 year old woman with schizophrenia develop fatigue 12 days after switching from olanzapine to closapine [bilirubin normal, ALT 181 U/L, Alk P not given], resolving within 2 weeks of stopping and recurring [fever and ALT 69 U/L] at a dose of 100 mg daily).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R60">Hern&#x000e1;ndez N, Bessone F, S&#x000e1;nchez A, di Pace M, Brahm J, Zapata R, A Chirino R, et al. Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports. Ann Hepatol 2014; 13: 231-9.  [<a href="/pubmed/24552865" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24552865</span></a>]<div><i>(Systematic review of literature of drug induced liver injury in Latin American countries published from 1996 to 2012 identified 176 cases, but none were attributed to clozapine or olanzapine).</i></div></div></li><li><div class="bk_ref" id="Clozapine.R61">Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al.; United States Drug Induced Liver Injury Network. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. Gastroenterology 2015; 148: 1340-52.e7.  [<a href="/pmc/articles/PMC4446235/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4446235</span></a>] [<a href="/pubmed/25754159" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25754159</span></a>]<div><i>(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, 5 [0.7%] were attributed to antipsychotic medications, including 3 to quetiapine and 2 to olanzapine, but none to clozapine).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK548412</span><span class="label">PMID: <a href="/pubmed/31643731" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">31643731</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Clotrimazole/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Cobimetinib/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK548412&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK548412/?report=reader">PubReader</a></li><li><a href="/books/NBK548412/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK548412" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK548412" style="display:none" title="Cite this Page"><div class="bk_tt">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.  Clozapine. [Updated 2017 Oct 16].<span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK548412/pdf/Bookshelf_NBK548412.pdf">PDF version of this page</a> (135K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Bulk Download</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://ftp.ncbi.nlm.nih.gov/pub/litarch/29/31/" ref="pagearea=source-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Bulk download LiverTox data from FTP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Overviews</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/intro/">Introduction</a></li><li><a href="/books/n/livertox/Causality/">Causality</a></li><li><a href="/books/n/livertox/ClinicalCourse/">Clinical Course</a></li><li><a href="/books/n/livertox/ClinicalOutcome/">Clinical Outcomes</a></li><li><a href="/books/n/livertox/ImmuneFeatures/">Immune Features</a></li><li><a href="/books/n/livertox/DrugCategory/">Likelihood Scale</a></li><li><a href="/books/n/livertox/Phenotypes_intro/">Phenotypes</a></li><li><a href="/books/n/livertox/Severity/">Severity Grading</a></li><li><a href="/books/n/livertox/CaseReport/">Writing a Case Report</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Support Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/">LiverTox Homepage</a></li><li><a href="/books/n/livertox/aboutus/">About LiverTox</a></li><li><a href="/books/n/livertox/editorsandreviewers/">Editors and Review Committee</a></li><li><a href="/books/n/livertox/alert/">Meetings and News</a></li><li><a href="/books/n/livertox/abbreviation/">Abbreviations Used</a></li><li><a href="/books/n/livertox/glossary/">Glossary</a></li><li><a href="/books/n/livertox/resource/">Information Resources</a></li><li><a href="/books/n/livertox/disclaimer/">User/Medical Advice Disclaimer</a></li><li><a href="/books/n/livertox/Contactus/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>OTHER REFERENCE LINKS</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;pubmedfilters=true&amp;term=(Clozapine/AE)+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D%3A%222999/12/31%22%5BEDat%5D)" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Recent References on Clozapine: from PubMed.gov</a></li><li><a href="https://clinicaltrials.gov/ct2/results?term=Clozapine" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Trials on Clozapine: from ClinicalTrials.gov</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4860032" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pcsubstance&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pcsubstance&amp;IdsFromResult=4860032" ref="log$=recordlinks">PubChem Substance</a><div class="brieflinkpop offscreen_noflow">Related PubChem Substances</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4860032" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/8515788" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Clozapine-induced agranulocytosis. Incidence and risk factors in the United States.</a><span class="source">[N Engl J Med. 1993]</span><div class="brieflinkpop offscreen_noflow">Clozapine-induced agranulocytosis. Incidence and risk factors in the United States.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">N Engl J Med. 1993 Jul 15; 329(3):162-7. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/16585434" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.</a><span class="source">[Am J Psychiatry. 2006]</span><div class="brieflinkpop offscreen_noflow">Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe RS, Davis CE, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Am J Psychiatry. 2006 Apr; 163(4):600-10. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/2292234" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia.</a><span class="source">[Drugs. 1990]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Fitton A, Heel RC. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Drugs. 1990 Nov; 40(5):722-47. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/18759705" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> The safety of clozapine in the elderly.</a><span class="source">[Expert Opin Drug Saf. 2008]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> The safety of clozapine in the elderly.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Gareri P, De Fazio P, Russo E, Marigliano N, De Fazio S, De Sarro G. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Expert Opin Drug Saf. 2008 Sep; 7(5):525-38. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/27521016" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Quetiapine : A Review of its Use in Schizophrenia.</a><span class="source">[CNS Drugs. 1998]</span><div class="brieflinkpop offscreen_noflow">Quetiapine : A Review of its Use in Schizophrenia.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Gunasekara NS, Spencer CM. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">CNS Drugs. 1998 Apr; 9(4):325-40. </em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=31643731" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=31643731" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=60467d20a19b7255ae03d18c">Clozapine - LiverTox</a><div class="ralinkpop offscreen_noflow">Clozapine - LiverTox<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2021-03-08T14:38:09-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@9.2&amp;Host=portal103&amp;ncbi_phid=CE8A7B170467CDC100000000000E0005&amp;ncbi_session=CE8A7B170467D201_0014SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK548412%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK548412&amp;ncbi_domain=livertox&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK548412/&amp;ncbi_pagename=Clozapine - LiverTox - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8A7B170467D201_0014SID /projects/books/PBooks@9.2 portal103 v4.1.r621975 Fri, Dec 18 2020 02:56:50 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>